UPB · Upstream Bio

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

890 Winter Street, Waltham, MA, 02451, United States
Biotechnology
Healthcare

Market Cap

276M

52 Wk Range

$4.86 - $33.68

Previous Close

$5.04

Open

$5.07

Volume

1,010,578

Day Range

$4.66 - $5.10

Enterprise Value

25.0M

Cash

261.3M

Avg Qtr Burn

-35.62M

Insider Ownership

14.78%

Institutional Own.

92.46%

Qtr Updated

Jun 30th 2026